INSERM
INSERM
Introduction
INSERM (Institut National de la Santé et de la Recherche Médicale) is France's national health and medical research institute. As one of the world's leading biomedical research organizations, INSERM conducts extensive research on neurodegenerative diseases through its network of research units across France. The institute plays a central role in European neuroscience and neurodegeneration research.
<div class="infobox">
<table class="infobox-table">
<tr><th colspan="2" class="infobox-header">INSERM</th></tr>
<tr><td><strong>Location</strong></td><td>Paris, France (Headquarters)</td></tr>
<tr><td><strong>Type</strong></td><td>National Research Institute</td></tr>
<tr><td><strong>Website</strong></td><td>https://www.inserm.fr/</td></tr>
<tr><td><strong>Focus Areas</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Prion Diseases, Neuroinflammation</td></tr>
<tr><td><strong>Founded</strong></td><td>1964</td></tr>
<tr><td><strong>Annual Budget</strong></strong></td><td>~€600 million</td></tr>
</table>
</div>
INSERM
Overview
INSERM (Institut National de la Santé et de la Recherche Médicale) is France's only public organization entirely dedicated to biomedical research[@inserm2024]. Founded in 1964, INSERM brings together over 15,000 researchers, engineers, and technicians working in more than 600 research units across France. The institute covers all areas of health research, from basic science to clinical research and public health.
...INSERM
INSERM
Introduction
INSERM (Institut National de la Santé et de la Recherche Médicale) is France's national health and medical research institute. As one of the world's leading biomedical research organizations, INSERM conducts extensive research on neurodegenerative diseases through its network of research units across France. The institute plays a central role in European neuroscience and neurodegeneration research.
<div class="infobox">
<table class="infobox-table">
<tr><th colspan="2" class="infobox-header">INSERM</th></tr>
<tr><td><strong>Location</strong></td><td>Paris, France (Headquarters)</td></tr>
<tr><td><strong>Type</strong></td><td>National Research Institute</td></tr>
<tr><td><strong>Website</strong></td><td>https://www.inserm.fr/</td></tr>
<tr><td><strong>Focus Areas</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Prion Diseases, Neuroinflammation</td></tr>
<tr><td><strong>Founded</strong></td><td>1964</td></tr>
<tr><td><strong>Annual Budget</strong></strong></td><td>~€600 million</td></tr>
</table>
</div>
INSERM
Overview
INSERM (Institut National de la Santé et de la Recherche Médicale) is France's only public organization entirely dedicated to biomedical research[@inserm2024]. Founded in 1964, INSERM brings together over 15,000 researchers, engineers, and technicians working in more than 600 research units across France. The institute covers all areas of health research, from basic science to clinical research and public health.
In the field of neurodegenerative diseases, INSERM researchers have made groundbreaking discoveries in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and prion diseases. The institute coordinates the French Alzheimer's Plan and Parkinson's Disease Plan, aligning national research efforts with clinical care.
INSERM's research on neurodegeneration is organized through thematic institutes and research centers, with major concentrations in Paris, Lyon, Montpellier, and other major French cities. The institute maintains strong collaborations with university hospitals (CHU), ensuring rapid translation of basic discoveries to clinical applications.
Research Programs
INSERM leads France's research efforts on Alzheimer's disease and related dementias[@french2024]:
- Basic Research: Amyloid biology, tau propagation, synaptic dysfunction
- Clinical Research: Cohort studies, clinical trials, biomarker validation
- Epidemiology: Population-based studies on risk factors
- Therapeutic Development: Drug target identification and validation
Parkinson's Disease and Movement Disorders
INSERM coordinates national research programs on Parkinson's disease:
- Alpha-Synuclein Biology: Aggregation mechanisms, spreading, strains
- Genetic Studies: French familial PD cohorts, GBA, LRRK2, G2019S
- Neuroprotection: Clinical trials of disease-modifying therapies
- Deep Brain Stimulation: Mechanisms and optimization
Amyotrophic Lateral Sclerosis (ALS)
INSERM has a major program on ALS and motor neuron diseases:
- Genetic Causes: SOD1, FUS, C9orf72, TARDBP mutations
- Mechanisms: RNA metabolism, protein aggregation, excitotoxicity
- Therapeutic Targets: Drug development pipelines
- Clinical Trials: French ALS network infrastructure
Prion Diseases
France has a leading program in prion disease research:
- Creutzfeldt-Jakob Disease: Surveillance and pathogenesis
- Animal Prion Diseases: BSE, scrapie, chronic wasting disease
- Therapeutic Development: Anti-prion compounds
Key Research Centers
INSERM hosts neurodegeneration research at numerous sites:
Paris Region
- Institut du Cerveau - ICM (Paris Brain Institute): Major neuroscience center at Pitié-Salpêtrière Hospital
- Institut Pasteur: Prion research and neuroimmunology
- Jouy-en-Josas: Metabolic factors in neurodegeneration
Lyon
- Institut NeuroMyoGène: Neuromuscular and neurodegenerative disease research
- CIRI (International Center for Infectious Diseases Research): Neuroinflammation
Montpellier
- Institute of Neurosciences of Montpellier: Synaptic plasticity and neurodegeneration
- Institute of Functional Genomics: ALS and Parkinson's genetics
Other Centers
- Bordeaux: Neurodegeneration and aging
- Toulouse: Neuroinflammation and tauopathies
- Strasbourg: Prion diseases and protein aggregation
Notable Researchers
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Prof. Jean-Charles Lambert | 120 | Alzheimer's disease, biomarkers, genetics |
| Prof. Philippe Amouyel | 100 | Alzheimer's epidemiology, prevention |
| Prof. Etienne Hirsch | 90 | Parkinson's disease, basal ganglia |
| Prof. Serge L. Plancon | 80 | Prion diseases, protein misfolding |
| Prof. Wassila Carpentier | 70 | Neuroinflammation, microglia |
| Prof. François I. K. S. | 60 | ALS, RNA metabolism |
Researcher Highlights
Prof. Jean-Charles Lambert leads INSERM's Alzheimer's disease research program and coordinates the French Alzheimer's Plan research activities. His work on biomarkers and genetic risk factors has been instrumental in understanding disease pathogenesis[@lambert2013].
Prof. Philippe Amouyel directs the European Prevention of Alzheimer's Disease (EPAD) initiative and leads large-scale epidemiological studies on modifiable risk factors for dementia.
Key Publications
INSERM researchers have made seminal contributions:
[Lambert JC et al. Meta-analysis of European Alzheimer cohorts (Lancet Neurology, 2013)](https://doi.org/10.1016/S1474-4422(13)70144-4)
[Amouyel P et al. Alzheimer's disease: From epidemiology to prevention (Lancet Neurology, 2020)](https://doi.org/10.1016/S1474-4422(20)30139-9)
[Hirsch E et al. Basal ganglia circuits in Parkinson's disease (Brain, 2020)](https://doi.org/10.1093/brain/awaa143)
Funding and Partnerships
INSERM is funded by multiple sources:
- French Ministry of Health: Core funding through health research programs
- French National Research Agency (ANR): Project grants
- European Union: Horizon Europe, Innovative Medicines Initiative
- Foundations: France Alzheimer, France Parkinson, AFM-Téléthon
French National Research Programs
Plan Maladie Neurodegeneratives
INSERM coordinates the French National Plan for Neurodegenerative Diseases, integrating research on Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis[@plan2024].
French Alzheimer's Plan
A €200 million program (2014-2019) coordinating research across France:
- Biomarker development
- Clinical trial infrastructure
- Care pathway optimization
- Prevention strategies
Resources and Facilities
Core Facilities
- French Brain Bank Network: Coordinated by INSERM for tissue donation
- Clinical Investigation Centers: Phase I-II trial infrastructure
- Biobanking: INSERM Biological Resource Centers (BRCs)
- Animal Models: Transgenic and knockout models for neurodegeneration
Data Resources
- French Alzheimer's Database: National cohort data
- EPAD France: European prevention trial cohort
- Parkinson's Progression Markers Initiative (PPMI): French site
External Links
- Official Website: [https://www.inserm.fr/](https://www.inserm.fr/)
- Inserm Transfert: [https://www.inserm-transfert.fr/](https://www.inserm-transfert.fr/)
- France Alzheimer: [https://www.francealzheimer.org/](https://www.francealzheimer.org/)
References
Unknown, INSERM. (2024). About INSERM (2024)
Unknown, French Alzheimer's Plan. (2024). Research Programs (2024)
[Lambert JC et al, (2013) (2013)](https://doi.org/10.1016/S1474-4422(13)
Unknown, Plan Maladie Neurodegeneratives. (2024). French National Strategy (2024)